Monopar Therapeutics

Monopar Therapeutics

Yahoo Finance • 14 days ago

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, t... Full story

Yahoo Finance • 17 days ago

Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment

(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and... Full story

Yahoo Finance • 2 months ago

Monopar's ALXN1840 Shows Significant Copper Reduction In Phase 2 Trial For Wilson Disease

(RTTNews) - Monopar Therapeutics Inc. (MNPR), on Monday announced that Hepatology Communications has published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-l... Full story

Yahoo Finance • 2 months ago

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, to... Full story

Yahoo Finance • 3 months ago

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs,... Full story

Yahoo Finance • 3 months ago

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical nee... Full story

Yahoo Finance • 5 months ago

Broadcom Stock Sees Improved Relative Strength Rating

In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy? Continue Reading... Full story

Yahoo Finance • 8 months ago

Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05

* Monopar Therapeutics press release [https://seekingalpha.com/pr/20306013-monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent-developments] (MNPR [https://seekingalpha.com/symbol/MNPR]): Q3 GAAP EPS of -$0.48 mi... Full story

Yahoo Finance • 8 months ago

Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded DraftKings (DNKG) t... Full story

Yahoo Finance • 8 months ago

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, i... Full story

Yahoo Finance • 9 months ago

How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments

The consensus analyst price target for AstraZeneca has seen a slight upward revision, rising from £138.16 to £140.96, as market expectations are recalibrated. This adjustment comes amid evolving analyst perspectives that balance optimism a... Full story

Yahoo Finance • 9 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 10 months ago

Monopar Therapeutics announces pricing of $135M offering

* Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) announced on Tuesday the pricing of an underwritten registered offering [https://seekingalpha.com/pr/20242206-monopar-therapeutics-inc-announces-pricing-of-135-m... Full story

Yahoo Finance • 10 months ago

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients w... Full story

Yahoo Finance • 10 months ago

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs,... Full story

Yahoo Finance • 10 months ago

CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded CoreWeave (CRWV)... Full story

Yahoo Finance • 10 months ago

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs,... Full story

Yahoo Finance • 10 months ago

Monopar a new outperform at Oppenheimer on Wilson disease candidate

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Oppenheimer has initiated Monopar Therapeutics at outperform citing the potential of a candidate for the genetic disorder Wilson disease it acquired from AstraZeneca... Full story

Yahoo Finance • 12 months ago

Monopar therapeutics director Tsuchimoto sells $356k in stock

Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, netting approximately $356,170. Th... Full story

Yahoo Finance • 12 months ago

Monopar therapeutics director Starr sells $672k in stock

Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% return over the past year, according to Invest... Full story